"Special treatment": BiDil, Tuskegee, and the logic of race.
BiDil, a drug approved in 2005 by the FDA only for African Americans, was seen by many as almost reparations for the horrors of the Tuskegee Syphilis Study (1932-72) where treatment for black men was denied. The logic of race, however, rather than racism, links BiDil to the past many thought it was escaping.
Reverby
Susan M
SM
Wellesley College.
D001741:Black or African American; D002986:Clinical Trials as Topic / Q000941:ethics; D017277:Drug Approval; D004338:Drug Combinations; D004992:Ethics, Medical; D006333:Heart Failure / Q000188:drug therapy / Q000208:ethnology*; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use*; D007548:Isosorbide Dinitrate / Q000627:therapeutic use*; D008297:Male; D011287:Prejudice; D044469:Racial Groups / Q000235:genetics*; D013587:Syphilis / Q000188:drug therapy / Q000208:ethnology; D014665:Vasodilator Agents / Q000627:therapeutic use*; D028761:Withholding Treatment / Q000941:ethics*
D004338:Drug Combinations; D014665:Vasodilator Agents; C431665:isosorbide-hydralazine combination; D006830:Hydralazine; D007548:Isosorbide Dinitrate